ClinicalTrials.gg
CompletedNCT04172987Updated Mar 27, 2023Results posted

A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants

A Phase 1 interventional study of Tirzepatide and EE/NGM in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-27.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

The purpose of this study is to look at how the body processes the commonly prescribed birth control pill, ethinylestradiol + norgestimate (EE/NGM), in healthy female participants and the effect of tirzepatide on how EE/NGM is processed by the body. Information about any side effects that may occur will also be collected.

Screening is required within 28 days prior to the start of the study. For each participant, the study will last about 20 weeks, including screening.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Overtly healthy females as determined by medical history, physical examination, and other screening procedures
  • Have a (BMI) equal to or above 18.5 kilograms per meter squared (kg/m²), at screening
  • Are not intending to start a family within 2 months after the study

Exclusion criteria

Exclusion Criteria:

  • Have known allergies to either tirzepatide or ethinylestradiol or norgestimate or related compounds
  • Have a medical condition or medical history that precludes the taking of combined oral
  • Have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis), elevation in serum amylase or lipase or gastrointestinal (GI) disorder (eg, relevant esophageal reflux or gall bladder disease) or any GI disease which impacts gastric emptying (eg, gastric bypass surgery, pyloric stenosis, with the exception of appendectomy) or could be aggravated by glucagon-like peptide-1 (GLP-1) analogs or dipeptidyl peptidase IV (DPP-IV) inhibitors
  • Have used hormonal implants or received hormonal injections in the past 12 months
  • Unwilling to comply with smoking restrictions during the study
  • Is a known user of drugs of abuse
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Ethinyl Estradiol + Norgestimate (EE/NGM) Alone (Period 1)

    Participants received a 28-day packet of a combination oral contraceptive (OC) containing 21 days of tablets that consist of active ingredients (0.035 mg ethinyl estradiol (EE) and 0.25 mg norgestimate (NGM)) self-administered orally once-daily (QD) on Day 1 to Day 21, and 7 days of non-active tablets self-administer orally QD on Day 22 to Day 28 approximately the same time each day.

    Drug: EE/NGM

  • Experimental
    EE/NGM + Tirzepatide (Period 2)

    Participants received a 28-day packet of a combination OC containing 21 days of tablets that consist of active ingredients (0.035 mg EE and 0.25 mg NGM) self-administered orally QD on Day 1 to Day 21, and 7 days of non-active tablets self-administer orally QD on Day 22 to Day 28 approximately the same time each day and a single dose 5 mg tirzepatide administered subcutaneously (SC).

    Drug: Tirzepatide · Drug: EE/NGM

Interventions

  • Administered SC

    Also known as: LY3298176

  • DrugEE/NGM

    Combination oral contraceptive administered orally

06

What researchers measure

Primary outcomes

  1. Period 1 and Period 2, Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) Within 1 Dosing Interval (AUC[0-tau]) of Ethinylestradiol (EE)

    Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) Within 1 Dosing Interval (AUC\[0-tau\]) of Ethinylestradiol (EE)

    Time frame: Period 1 and Period 2: Predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48 hours postdose

  2. Period 1 and Period 2, PK: Maximum Concentration (Cmax) of EE

    PK: Cmax of EE

    Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48 hours postdose

  3. Period 1 and Period 2, PK: Area Under the Concentration Versus Time Curve (AUC) Within 1 Dosing Interval (AUC[0-tau]) of Norelgestromin (NGMN)

    PK: Area Under the Concentration Versus Time Curve (AUC) Within 1 Dosing Interval (AUC\[0-tau\]) of Norelgestromin (NGMN)

    Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48 hours postdose

  4. Period 1 and Period 2, PK: Cmax of Norelgestromin (NGMN)

    PK: Cmax of Norelgestromin (NGMN)

    Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48 hours postdose

07

Results

Posted Mar 27, 2023

Participant flow

Lead In Period
Participant flow — Lead In Period
MilestoneOverall Study
Started40
Received at least one dose of oc40
Completed38
Not completed2
Withdrew: Adverse event1
Withdrew: Protocol violation1
Period 1
Participant flow — Period 1
MilestoneOverall Study
Started38
Received at least one dose of oc38
Completed37
Not completed1
Withdrew: Physician decision1
Period 2
Participant flow — Period 2
MilestoneOverall Study
Started37
Received at least one dose of oc37
Received at least 1 dose of tirzepatide28
Completed28
Not completed9
Withdrew: Adverse event5
Withdrew: Dosing termination by sponsor4

Outcome measures

PrimaryPeriod 1 and Period 2, Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) Within 1 Dosing Interval (AUC[0-tau]) of Ethinylestradiol (EE)

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) Within 1 Dosing Interval (AUC\[0-tau\]) of Ethinylestradiol (EE)

Time frame:
Period 1 and Period 2: Predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48 hours postdose
Reported as:
Geometric mean · picogram hour per milliliter (pg*h/mL)
Period 1 and Period 2, Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) Within 1 Dosing Interval (AUC[0-tau]) of Ethinylestradiol (EE)
picogram hour per milliliter (pg*h/mL)OC (0.035 mg EE and 0.25 mg NGM)OC (0.035 mg EE and 0.25 mg NGM) + 5 mg Tirzepatide
Period 1 and Period 2, Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) Within 1 Dosing Interval (AUC[0-tau]) of Ethinylestradiol (EE)966 ± 40811 ± 41
PrimaryPeriod 1 and Period 2, PK: Maximum Concentration (Cmax) of EE

PK: Cmax of EE

Time frame:
Predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48 hours postdose
Reported as:
Geometric mean · picogram per milliliter pg/mL
Period 1 and Period 2, PK: Maximum Concentration (Cmax) of EE
picogram per milliliter pg/mLOC (0.035 mg EE and 0.25 mg NGM)OC (0.035 mg EE and 0.25 mg NGM) + 5 mg Tirzepatide
Period 1 and Period 2, PK: Maximum Concentration (Cmax) of EE119 ± 3349.6 ± 63
PrimaryPeriod 1 and Period 2, PK: Area Under the Concentration Versus Time Curve (AUC) Within 1 Dosing Interval (AUC[0-tau]) of Norelgestromin (NGMN)

PK: Area Under the Concentration Versus Time Curve (AUC) Within 1 Dosing Interval (AUC\[0-tau\]) of Norelgestromin (NGMN)

Time frame:
Predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48 hours postdose
Reported as:
Geometric mean · pg*h/mL
Period 1 and Period 2, PK: Area Under the Concentration Versus Time Curve (AUC) Within 1 Dosing Interval (AUC[0-tau]) of Norelgestromin (NGMN)
pg*h/mLOC (0.035 mg EE and 0.25 mg NGM)OC (0.035 mg EE and 0.25 mg NGM) + 5 mg Tirzepatide
Period 1 and Period 2, PK: Area Under the Concentration Versus Time Curve (AUC) Within 1 Dosing Interval (AUC[0-tau]) of Norelgestromin (NGMN)19900 ± 2714600 ± 67
PrimaryPeriod 1 and Period 2, PK: Cmax of Norelgestromin (NGMN)

PK: Cmax of Norelgestromin (NGMN)

Time frame:
Predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48 hours postdose
Reported as:
Geometric mean · pg/mL
Period 1 and Period 2, PK: Cmax of Norelgestromin (NGMN)
pg/mLOC (0.035 mg EE and 0.25 mg NGM)OC (0.035 mg EE and 0.25 mg NGM) + 5 mg Tirzepatide
Period 1 and Period 2, PK: Cmax of Norelgestromin (NGMN)2070 ± 27892 ± 74

Adverse events

Collected over Lead-In Up To 15 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lead-in: OC ( 0.035 mg EE and 0.25 mg NGM)0/40 (0%)0/40 (0%)9/40 (22.5%)
Period 1: OC ( 0.035 mg EE and 0.25 mg NGM)0/38 (0%)0/38 (0%)10/38 (26.3%)
Period 2: OC ( 0.035 mg EE and 0.25 mg NGM) + 5 mg Tirzepatide0/28 (0%)0/28 (0%)18/28 (64.3%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventLead-in: OC ( 0.035 mg EE and 0.25 mg NGM)Period 1: OC ( 0.035 mg EE and 0.25 mg NGM)Period 2: OC ( 0.035 mg EE and 0.25 mg NGM) + 5 mg Tirzepatide
NauseaGastrointestinal disorders4/401/3811/28
Decreased appetiteMetabolism and nutrition disorders2/401/386/28
VomitingGastrointestinal disorders1/400/385/28
HeadacheNervous system disorders1/404/385/28
Abdominal discomfortGastrointestinal disorders2/401/384/28
Abdominal painGastrointestinal disorders1/401/384/28
Abdominal distensionGastrointestinal disorders2/400/383/28
ChillsGeneral disorders0/400/383/28
PainGeneral disorders0/400/383/28
Corona virus infectionInfections and infestations0/400/382/28

Baseline characteristics

All participants who received at least one dose of oral contraceptive or tirzepatide.

Age, Continuous
Age, Continuous(years)Overall Study
Mean33.6 ± 7.6
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study
Female40
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall Study
Hispanic or Latino23
Not Hispanic or Latino17
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall Study
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American18
White20
More than one race1
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Overall Study
United States40
08

Study locations

1 site
  • Covance Dallas
    Dallas, Texas 75247, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Feb 2021, 11 months.

Results were first posted in Mar 2023, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2019
First posted
Nov 21, 2019
StartActual
Feb 26, 2020
Primary completionActual
Feb 9, 2021
CompletionActual
Feb 9, 2021
Results first posted
Mar 27, 2023
Last update
Mar 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04172987
Responsible party
Sponsor
First posted
Nov 21, 2019
Start date
Feb 26, 2020
Primary completion
Feb 9, 2021
Completion
Feb 9, 2021
Results posted
Mar 27, 2023
Last update
Mar 27, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion